- Summits
- Sponsorship
- Media Opportunities
- News
- About
With a staggering market value of €37.4 billion and over 1,300 companies in operation, France’s MedTech sector is not just thriving, it’s transforming the future of healthcare in Europe and beyond. According to the U.S. International Trade Administration, the French medical device industry is the second-largest in Western Europe, trailing only Germany. Exports alone reached €9.5 billion in 2023, representing 25% of total turnover.
And the momentum is only building.
The MedTech landscape in France is dominated by small and medium-sized enterprises (SMEs), with 92% of companies falling into this category. Interestingly, foreign-owned firms make up a third of all enterprises in the sector but generate two-thirds of its revenue—a clear sign of the international attractiveness of the French market.
Approximately 95,000 people are employed across the industry, which spans diagnostics, surgical robotics, imaging technologies, and implantable devices. Paris, Lyon, and Grenoble have emerged as regional innovation hubs, powered by partnerships between startups, hospitals, and public research institutions such as INSERM, CNRS, and the CEA.
Government support has also played a pivotal role. Under the ambitious €54 billion France 2030 investment plan, €7.5 billion is being funneled into the health sector. This includes targeted investments in artificial intelligence, digital health, and robotic surgery, aiming to make France a global reference point in cutting-edge medical technologies.
Also Read: Calling All MedTech Innovators: It’s Time to Nominate for MedTech Malta 2025 Awards
France’s growing role in the MedTech sector is gaining global recognition, reflected in MedTech World’s recent partnerships with LallianSe and MD101. These collaborations aim to connect French innovation with international investment, industry expertise, and opportunities for global scaling.
“Our partnership with LallianSe and MD101 is a testament to our mission of nurturing meaningful innovation in healthcare,” says Dr. Dylan Attard, CEO of MedTech World. “By combining our global MedTech network with LallianSe’s local knowledge and execution power and MD101’s network and market expertise, we’re opening doors for startups to reach new markets and create global health impact.”
Julie Rachline, founder and CEO of LallianSe, echoes the sentiment: “France has been leading innovation in healthcare in the past decades – surgery, robotics, AI among others. We have been amazingly good at innovating, but we need to improve our scaling and international outreach. Bringing our innovations into a global MedTech market is mandatory. That’s our goal with LallianSe, and that’s a key reason why this partnership with MedTech World and MD101 is so meaningful! MedTech World brings a platform for international visibility and scale. Together, we are accelerating the translation of patient-driven solutions from ideas to reality.”
Mathieu Charleux, CEO of MD101, emphasized: “This partnership creates a powerful ecosystem where innovation, expertise, and market access converge. LallianSe brings together France’s most promising MedTech innovators, while Medtech World provides the global platform for visibility and connection. MD101 complements this perfectly by transforming those innovations into market-ready solutions—we architect scalable business models, navigate complex regulatory landscapes, and orchestrate international expansion strategies. Together, we’re not just supporting individual companies; we’re building a comprehensive pipeline that takes French MedTech from breakthrough concept to worldwide commercial success.”
This triad of expertise, MedTech World’s global platform, LallianSe’s integrator and original model, and MD101’s regulatory and go-to-market precision, marks a pivotal step in supporting high-potential health technologies from concept to successful international commercialization.
For Medtech startups, this collaboration offers more than visibility – it offers a launchpad. From strategic guidance and international exposure to regulatory acceleration and investor access, LallianSe and MD101 provide a support structure that can turn ambition into economic success. This momentum is set to culminate at MedTech Malta 2025, taking place from November 12 to 14 at the iconic Mediterranean Conference Centre in Valletta. As one of the world’s premier MedTech gatherings, the event will spotlight France’s role in the global ecosystem while bringing together thought leaders, investors, regulators, and innovators from every corner of the globe.
Attendees can expect:
As France continues to foster a fertile environment for MedTech innovation, its presence at Malta 2025 will not only highlight its progress but also invite new alliances, investments, and ideas. For more information, connect with us at [email protected].
